PubMed ID:
19940299
Public Release Type:
Journal
Publication Year: 2009
Affiliation: Indiana University School of Medicine, Indianapolis, USA.
DOI:
https://doi.org/10.1056/NEJMoa0904452
Authors:
Gottlieb PA,
Becker DJ,
Gitelman SE,
Goland R,
Greenbaum CJ,
Krause-Steinrauf H,
Lachin JM,
Marks JB,
McGee PF,
Moran AM,
Pescovitz MD,
Raskin P,
Rodriguez H,
Schatz DA,
Skyler JS,
Type 1 Diabetes TrialNet Anti-CD20 Study Group,
Wherrett D,
Wilson DM
The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte-mediated diseases. It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes.